July 1996 SYNTHESIS 819

A Simple Stereoselective Synthesis of the Cholesterol Absorption Inhibitor (-)-SCH 48461

Manfred Braun,* Dietmar Galle

Institut für Organische Chemie und Makromolekulare Chemie der Universität Düsseldorf, D-40225 Düsseldorf, Germany Fax +49(211)8113085; E-mail: braunm@clio.rz.uni-duesseldorf.de

Received 9 February 1996

The cholesterol absorption inhibitor (3R,4S)-1 is synthesized in 91% ee by a stereoselective condensation of doubly deprotonated ester 2 and imine 3. The optical purity of the *trans*-diastereomer 1 obtained as the major isomer (trans/cis, 94:6) is enhanced to > 98% ee by a single recrystallization.

For decades, β -lactams have been known as highly efficient antibiotics. However, the azetidinone 1 has been found to display a completely different biological activity. Thus, a Schering-Plough research group reported recently that 1 acts as a potent inhibitor of intestinal cholesterol absorption, presumably by a novel mechanism of action.² The β -lactam 1 was first synthesized as a racemate, the resolution of which was accomplished by chromatography on a Chiracel OD column. A comparison of (-)-(3R,4S)-1, named SCH 48461, with ent-1 revealed that the former stereoisomer provides dramatically greater in vivo activity. Although an asymmetric synthesis described recently³ afforded (-)-1 it led to the formation of the undesired cis-diastereomer (93% ee) which had to be epimerized to a cis/trans-mixture (1:4) and finally separated. Considering this protocol to be fairly tedious, we decided to apply our esterenolate-imine condensation⁴ in order to synthesize SCH 48461 by a facile route (Scheme 1).

Scheme 1

For this purpose, readily available (R)-triphenylglycol $(4)^5$ is esterified by treatment with 5-phenylpentanoic chloride⁶ to the chiral ester 2. When ester 2 is doubly deprotonated by treatment with 2 equivalents of lithium diisopropylamide and subsequently allowed to react with imine 3, the azetidinone 1 is obtained besides triphenylglycol (4) which is removed by column chromatography. The $trans-\beta$ -lactam 1 is formed predominantly

(94:6) according to the 1 H NMR spectra 8 of the crude mixture of 1 and 4. After removal of the diol 4 and the minor *cis*-diastereomer by chromatography, the enantiomeric excess of *trans*-azetidinone 1 is determined to be 91% ee by 1 H NMR measurement in the presence of the chiral shift reagent Eu(hfc)₃. The enantiomeric purity of 1 is enhanced to > 98% ee by a single recrystallization from hexane/ethyl acetate. Thus, a straightforward, two-step route is opened to the novel drug SCH 48461 based on the versatile of chiral reagent triphenylglycol (4).

Scheme 2

The absolute configuration of the azetidinone 1 obtained from (R)-ester 2 is not only assigned by comparison of its optical rotation with the data described,^{2,3} but also by the CD spectrum which shows a strong negative Cotton effect. When the octant rule¹¹ is applied to (3R,4S)-1, the structure of which has been optimized by MOPAC-AM1 calculations,¹² both the aryl substituent at C-4 and the phenylpropyl side chain at C-3 turn out to be located in negative octants. The negative Cotton effect thus predicted is clearly confirmed by the circular dichroism.

Melting points (uncorrected) were determined with a Büchi melting point apparatus 510. Specific rotations were determined with a Perkin–Elmer 341 polarimeter. CD spectra: Jasco J 600. Mass spectra: Varian MAT CH-5. ¹H NMR spectra: Varian VXR 300. TLC: Silica gel 60 F₂₅₄ (Merck). Column chromatography: MN-Kieselgel 60, mesh size 0.04–0.063 mm (Macherey-Nagel). General remarks concerning the handling of lithium enolates are given in Ref. ¹³

820 Short Papers SYNTHESIS

(1'R)-5-Phenylpentanoic Acid 2'-Hydroxy-1',2',2'-triphenylethyl Ester [(R)-2]:

A 500-mL two-necked flask, connected to a combined nitrogenvacuum line, was equipped with a magnetic stirrer and a dropping funnel and charged with diol 4 (15.1 g, 52.0 mmol), pyridine (4.95 mL, 57 mmol) and anhyd CH₂Cl₂ (200 mL). The mixture was stirred at 0°C, and a solution of 5-phenylpentanoic chloride (10.3 g, 52.0 mmol) in CH₂Cl₂ (50 mL) was added through the dropping funnel. A white precipitate formed gradually. After stirring for 2 h at r.t., water (200 mL) was added in order to dissolve the hydrochloride, and the organic solvent was removed in a rotary evaporator. The product precipitated thereby and was collected in a suction filter, washed several times with water (300 mL), and air dried with suction for 1 h. The resulting cake was transferred to a 1-L flask and dissolved in toluene (500 mL). The mixture was concentrated by distillation of the solvent at atmospheric pressure until precipitation of the product started. Hexane (100 mL) was added and the mixture was kept in a freezer (-18°C) overnight. The crystalline product was collected in a suction filter, washed with hexane, and dried in vacuo (oil pump) to give (R)-2 (20 g, 85%); mp 191–192°C; $[\alpha]_D^{20}$ + 166 (c = 0.5, CHCl₃).

 $\begin{array}{cccc} C_{31}H_{30}O_3 & calc. & C~82.63 & H~6.72 \\ (450.6) & found & 82.45 & 6.70 \end{array}$

MS (70 eV): m/z = 450 (M⁺, 0.3), 183 (100).

 1 H NMR (CDCl₃/TMS): δ = 1.41–1.58 (m, 4 H, 3-H, 4-H), 2.24–2.27 (m, 2 H, 2-H), 2.48–2.52 (m, 2 H, 5-H), 2.79 (s, 1 H, OH), 6.69 [s, 1 H, PhC*H*(OH)], 7.02–7.57 (m, 20 H_{arom}).

(3R,4S)-1,4-Bis(4-methoxyphenyl)-3-(3-phenylpropyl)-2-azetidinone [(3R,4S)-1]:

A 100-mL two-necked flask, connected to a combined nitrogenvacuum line, was equipped with a magnetic stirrer and a septum. During the following manipulations, N₂ atmosphere was maintained in all flasks. Anhyd THF (40 mL) and i-Pr₂NH (3.04 mL, 21.8 mmol) were injected through the septum by a syringe. The mixture was stirred at -78 °C, and a 1.6 M solution of BuLi in hexane (14 mL, 21.8 mmol) was added. Stirring was continued for 30 min at 0°C in order to complete the formation of LDA. In a 250-mL two-necked flask, connected to the combined nitrogenvacuum line, a solution of the ester 2 (4.7 g, 10.8 mmol) in anhyd THF (100 mL) was stirred at -78 °C. The precooled (-78 °C) solution of LDA, prepared as described above, was added by a cannula, whereby the 250-mL flask was slightly evacuated. The stirred mixture reached -65° C within 2 h and was then cooled again to -78 °C. A solution of 3 (2.48 g, 10.8 mmol) in anhyd THF (40 mL) was precooled to -78 °C and added by means of a cannula. The mixture was allowed to reach r.t. within 15 h and transferred to a separatory funnel. Et₂O (200 mL) was added, and the mixture was washed with 1 N HCl $(2 \times 80 \text{ mL})$. The combined aqueous layers were extracted with Et_2O (2 × 50 mL). The combined organic phases were washed with brine (100 mL), dried (MgSO₄), and concentrated in a rotary evaporator. The crude product thus obtained

was purified by column chromatography on silica gel (hexane/ CHCl₃/EtOAc, 8:4:1). The fraction corresponding to R_f 0.35 (diol 4: R_f 0.25) was collected to give crystalline 1 as a pure diastereomer; ee 91% according to 1 H NMR measurement with Eu(hfc)₃; yield: 2.5 g (58%); $[\alpha]_D^{20} - 17.3$ (c = 0.51, MeOH), corresponding to 90% ee [Lit. 2 [α]_D - 19.3 (c = 0.623, MeOH)]. Recrystallization (hexane/ EtOAc, 1:1) afforded (3 R_s 4S)-1 in > 98% ee; yield: 1.8 g (41%); mp 47–48°C [Lit. 2 46.5–48°C]; $[\alpha]_D - 19.0$ (c = 0.48, MeOH). The spectroscopic data were in accordance with those described in Lit. 2 H NMR (CDCl₃/TMS): $\delta = 1.75-1.94$ (m, 4 H, CH₂CH₂), 2.63 (t, J = 7 Hz, 2 H, PhCH₂), 3.09–3.07 (m, 1 H, 3-H), 3.71 (s, 3 H, OCH₃), 3.77 (s, 3 H, OCH₃), 4.54 (d, J = 2.4 Hz, 1 H, 4-H), 6.75 (d, J = 9 Hz, 2 H_{arom}), 6.87 (d, J = 8.7 Hz, 2 H_{arom}), 7.12–7.29 (m, 9 H....)

¹H NMR (CDCl₃/TMS): Mixture of 1 (91% ee; 40 mg) and Eu(hfc)₃ (75 mg): (3*R*,4*S*)-1: $\delta = 3.78$ (s, 3 H, OCH₃); (3*S*,4*R*)-1: $\delta = 3.94$ (s, 3 H, OCH₃).

This work was supported by the Fonds der Chemischen Industrie. We would like to thank Mr. M. Tolksdorf for recording the CD spectra.

- Morin, R. B.; Gorman, M. Chemistry and Biology of β-Lactam-Antibiotics;
 Vol. 1-3; Academic: New York, 1982.
 Georg, G. I., Ed. The Organic Chemistry of β-Lactams;
 VCH: Weinheim, 1993.
 Hart, D.J.; Ha, D.-C. Chem. Rev. 1989, 89, 1447.
- (2) Burnett, D. A.; Caplen, M. A.; Davis, H. R., Jr.; Burrier, R. E.; Clader, J. W. J. Med. Chem. 1994, 37, 1733.
- (3) Burnett, D.A. Tetrahedron Lett. 1944, 35, 7339.
- (4) Braun, M.; Sacha, H.; Galle, D.; El-Alali, A. Tetrahedron Lett. 1995, 36, 4213.
- (5) Braun, M.; Gräf, S.; Herzog, S. Org. Synth. 1993, 72, 32.
- (6) Fieser, L. F.; Berliner, E.; Bondhus, F. J.; Chang, F. C.; Dauben, W. G.; Ettlinger, M. G.; Fawaz, G.; Fields, M.; Heidelberger, C.; Heymann, H.; Vaughan, W. R.; Wilson, A. G.; Wilson, E.; Wu, M.-i.; Leffler, M. T.; Hamlin, K. E.; Matson, E. J.; Moore, E. E.; Moore, M. B.; Zaugg, H. E. J. Am. Chem. Soc. 1948, 70, 3174.
- (7) Hantzsch, A.; Schwab, O. Ber. Dtsch. Chem. Ges. 1901, 34, 822.
- (8) In the cis-isomer of 1, the doublet (J = 6 Hz) of 4-H is observed at $\delta = 5.11$ (see Ref. 2) which differs distinctly from the corresponding signal of 1 synthesized by us (see experimental).
- (9) Eu(hfc)₃ = Tris[3-(2,2,3,3,4,4,4-heptafluoro-1-hydroxybutylidene)-d-camphorato]europium (Aldrich)
- (10) Braun, M.; Devant, R. Tetrahedron Lett. 1984, 25, 5031.
 Braun, M. Angew. Chem. 1987, 99, 24; Angew. Chem. Int. Ed. Engl. 1987, 26, 24.
 Braun, M.; Sacha, H. J. Prakt. Chem. 1993, 335, 653.
- (11) Galle, D.; Tolksdorf, M.; Braun, M. Tetrahedron Lett. 1995, 36, 4217, and references given therein.
- (12) MOPAC 6.0 package: Stewart, J.J.P. QCPE #455.
- (13) Devant, R.; Mahler, U.; Braun, M. Chem. Ber. 1988, 121, 397.